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Abstract
The inefficient clearance of dying cells can lead to abnormal immune responses, such as 
unresolved inflammation and autoimmune conditions. We show that tumor suppressor p53 
controls signaling-mediated phagocytosis of apoptotic cells through its target, Death Domain1α 
(DD1α), which suggests that p53 promotes both the proapoptotic pathway and postapoptotic 
events. DD1α appears to function as an engulfment ligand or receptor that engages in homophilic 
intermolecular interaction at intercellular junctions of apoptotic cells and macrophages, unlike 
other typical scavenger receptors that recognize phosphatidylserine on the surface of dead cells. 
DD1α-deficient mice showed in vivo defects in clearing dying cells, which led to multiple organ 
damage indicative of immune dysfunction. p53-induced expression of DD1α thus prevents 
persistence of cell corpses and ensures efficient generation of precise immune responses.
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During development, tissue restoration, and response to injury, numerous cells are damaged 
and destined to undergo cell death or apoptosis. Thus, rapid and efficient clearance of cell 
corpses is a vital prerequisite for homeostatic maintenance of tissue health (1, 2). Failure to 
clear dying cells can lead to the accumulation of autoantigens in tissues that foster diseases, 
such as chronic inflammatory diseases, autoimmune diseases, and developmental 
abnormalities (1–4). Engulfment of apoptotic cells is an active process coordinated by 
receptors on phagocytes and ligands on apoptotic cells (5). The exposure of 
phosphatidylserine (PtdSer) on the surface of dying cells is a key signal that facilitates 
recognition and clearance by neighboring phagocytes (6). PtdSer on apoptotic cells can be 
recognized directly by phagocytic receptors— such as T-cell immunoglobulin and mucin 
domain-1, −3, and −4 (TIM-1, TIM-3, and TIM-4); brain-specific angiogenesis inhibitor 1 
(BAI1); and Stabilin-2— or indirectly via soluble bridging proteins [milk fat globule–EGF-
factor 8 (MFG-E8) and complement component (C1q)] to engage in engulfment of apoptotic 
cells (7–13).
The p53 tumor suppressor is indispensable for maintenance of genomic integrity (14–16). 
p53 functions as a transcription factor that is activated by various cellular stresses and 
governs multiple core programs in cells, including cell cycle arrest and apoptosis (17,18). 
p53 has been implicated in immune responses and inflammatory diseases (19–22). Several 
interferon (IFN)–inducible genes—such as interferon regulatory factors 5 and 9 (IRF5 and 
IRF9), interferon-stimulated gene 15 (ISG15), and Toll-like receptor 3 (TLR3)—are also 
p53 targets (20,23–25). Among others, it has been reported that the expression of forkhead 
box P3 (Foxp3), a master regulator of regulatory T cells (Tregs), is up-regulated by p53, and 
the number of Tregs was significantly reduced in p53-deficient mice (26,27). p53 also 
stimulates innate immunity by modulating macrophage function to non-cell-autonomously 
suppress tumorigenesis (28). Furthermore, although it remains unknown how p53 suppresses 
autoimmunity and excessive inflammation, accumulating studies have provided convincing 
evidence that p53 deficiency is closely associated with the development of autoimmune and 
inflammatory diseases in mice (21, 27,29–34).
Results
Identification of a postapoptotic target gene of p53, DD1α, an immunoglobulin superfamily 
receptor
Through microarray analysis of cDNA expression in EJ-p53 human bladder tumor cells with 
a tetracycline-regulated wild-type p53 (Wt-p53) overexpression system (35), we identified 
the gene encoding a transmembrane receptor, Death Domain1α (DD1α), as a downstream 
target gene of p53. DD1α mRNA and protein abundance were increased in response to 
genotoxic stress in a p53-dependent manner (Fig. 1A and figs. S1 and S2). The 
characterization of candidate p53 DNA binding consensus sequences by using reporter gene 
assays, chromatin immunoprecipitation–quantitative real-time polymerase chain reaction 
(ChIP-qPCR) and electrophoretic mobility-shift assay indicated that DD1α was a direct 
transcriptional target of p53 and that a consensus p53-binding site located at −5401 to −5420 
of the DD1α promoter conferred p53-dependent DD1α transactivation (Fig. 1B). DD1α is a 
member of the immunoglobulin superfamily and is also known as Gi24 or VISTA or PD-1H 
Yoon et al. Page 2
Science. Author manuscript; available in PMC 2017 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
or Dies1 (36–39). The DD1α protein migrated at ~50 kD on Western blots. Treatment of 
cells with the glycosylation inhibitor tunicamycin resulted in migration at ~30 kD, its 
predicted size (fig. S3). Northern blotting of various human tissues demonstrated relatively 
higher expression of DD1α in blood leukocytes, placenta, spleen, and heart and low 
amounts in lung, kidney, small intestine, and brain (Fig. 1C). Analysis of public database 
information (http://biogps.org/#goto=genereport&id=64115) (40, 41) also indicated that 
DD1α is expressed in immune cells, including macrophages, dendritic cells, monocytes, and 
myeloid and T cells. Although we identified DD1α as a bona fide p53 target gene, the 
depletion of endogenous DD1α by short hairpin RNAs (shRNAs) targeting different 
sequences in DD1α mRNA did not affect the DNA damage–induced apoptotic responses 
(figs. S4, S5C, S6, and S7B) in various cell systems carrying Wt-p53, which suggests that 
DD1α may not function as a typical p53 target gene. DD1α has similarity with several 
members of the immunoglobulin superfamily with the immunoglobulin variable (IgV) 
domain (Fig. 1C). We sought to determine whether TIM family proteins, as well as immune 
checkpoint coinhibitors, programmed cell death 1 (PD-1), and programmed death-ligand 1 
(PD-L1), might be regulated by p53 as seen for DD1α. The TIM family proteins, including 
TIM-1, TIM-2/3, and TIM-4, did not show increased expression in response to p53, but 
genes encoding PD-L1 and its receptor PD-1 showed increased expression in response to the 
p53 activator Nutlin-3 small molecule (10 µM) in MCF7 human breast cancer cells (Fig. 
1D). Genotoxic stimuli also activated transcription of PD-L1 and PD-1 in a p53-dependent 
manner. We verified p53-mediated activation of PD-L1 or PD-1 expression in several p53 
expression systems (Fig. 1D).
p53-induced expression of DD1α is essential for engulfment of apoptotic cells by 
phagocytes
TIM family molecules have an important role in phagocytosis of apoptotic cells (8, 9, 11). 
Because DD1α is structurally similar to TIM family proteins, we investigated whether 
increased abundance of DD1α induction on apoptotic cells could proceed to phagocytosis of 
dying cells. We depleted DD1α and p53 expression in MCF7 cells exposed to the apoptotic 
stimulus camptothecin (CPT) with two different DD1α shRNAs or p53 shRNAs (fig. S4A). 
About 60% of MCF7 cells expressing sh-luciferase (control), sh-DD1α, sh-p53, or both sh-
DD1α and si-p53 were apoptotic after CPT treatment (fig. S4B). We used a pH-sensitive dye 
(pHrodo), which emits red fluorescence only when located in the phagosome (pH ~5), to 
distinguish engulfed cells from unengulfed cells, and we calculated the phagocytic index 
(number of ingested cells per 100 macrophages) (42). To examine the functional role of 
DD1α or p53 in engulfment of dead cells, we used freshly isolated human monocyte–
derived macrophages (hu-MDMs) and measured engulfment of CPT-treated apoptotic MCF7 
cells. When control apoptotic MCF7 cells were incubated with hu-MDMs, the phagocytic 
index was ~50 or higher (Fig. 2A), which indicated that macrophages efficiently engulfed 
most of the apoptotic MCF7 cells present. However, when DD1α- or p53-depleted MCF7 
cells, or MCF7 cells depleted of both, were mixed with hu-MDMs, macrophages engulfed a 
lower number of apoptotic cells (phagocytic index of 10 to 25 for DD1α-depleted, ~30 for 
p53-depleted, and 10 to 25 for both p53 and DD1α-depleted) (Fig. 2A). Reexpression of 
DD1α in DD1α-depleted MCF7 cells restored engulfment amounts to similar to those of 
control cells (Fig. 2A). ZR75-1 human breast cancer cells with Wt-p53 were also used to 
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carry out the phagocytosis assay. Consistent with the behavior of MCF7 cells, when 
apoptotic ZR75-1 cells were incubated with hu-MDMs, DD1α or p53 depletion also 
decreased engulfment by macrophages (fig. S5). We also used two human cancer cell lines 
(BxPC-3, human pancreatic cancer cell line; and Hs888. T, human osteosarcoma cell line) 
that had very low DD1α expression, and we found that expression of DD1α was not 
increased by CPT (Fig. 2B, right). Apoptotic cells of both BxPC-3 and Hs888. T were less 
efficiently engulfed by hu-MDMs than by DD1α-expressing cell lines, such as MCF7, 
ZR75-1, and A375 (human melanoma cell line) (Fig. 2B, left, and fig. S6). However, ectopic 
expression of DD1α-HA in BxPC-3 and Hs888. T cells restored engulfment of dead cells by 
macrophages, which suggested that DD1α expression was sufficient to promote apoptotic 
cell engulfment by phagocytes (Fig. 2B).
We further examined the effects of p53 or DD1α deficiency on the phagocytosis of apoptotic 
cells with genetically modified mouse cells. Thymocytes isolated from wild-type (Wt), 
DD1α−/−, and p53−/− mice were exposed to ionizing radiation (IR) to induce apoptosis and 
activate DD1α expression. In Wt mouse thymocytes, but not p53−/− thymocytes, IR induced 
accumulation of DD1α mRNA expression, which indicated that the regulation of DD1α by 
p53 is also conserved in mice (fig. S7A). The IR-induced apoptotic responses of Wt and 
DD1α−/− thymocytes were comparable, but p53−/− thymocytes showed less apoptosis in 
response to IR. To use a similar apoptotic population of cells for each phagocytosis assay, 
we increased the dose of IR to p53−/− thymocytes (fig. S7B) in order to increase the 
proportion of apoptotic cells. About 60 to 70% of thymocytes from Wt, DD1α−/−, and 
p53−/− mice underwent apoptosis. Such cells were incubated with bone marrow-derived 
macrophages (m-BMDMs) from Wt mice, and the phagocytic potential was assessed with 
two different methods: flow cytometry–based analysis and time-lapse image-based analysis. 
Measurement of the m-BMDMs with increased red pHrodo signals among total m-BMDMs 
by flow cytometry revealed that apoptotic DD1α−/− or p53−/− thymocytes were less 
efficiently engulfed by macrophages than were Wt thymocytes (Fig. 2C). Time-lapse 
imaging analyses with carboxy-fluorescein succinimidyl ester (CFSE)–labeled (for green 
fluorescence) Wt, DD1α−/− and p53−/− thymocytes, and PKH26 red-labeled phagocytic m-
BMDMs showed defective phagocytosis of DD1α−/− or p53−/− thymocytes by macrophages 
(Fig. 2D and movies S1 to S3). Together, these data demonstrate that the p53-induced 
accumulation of DD1α is required for engulfment of apoptotic cells by phagocytes.
Impaired clearance of apoptotic cells in the DD1α-deficient mice
We tested whether DD1α deficiency caused defects in dead cell clearance in vivo in DD1α-
deficient mice. DD1α−/− mice were generated using the F1p-Cre system, and DD1α 
deficiency was confirmed in vivo (fig. S8). In mice with total body exposure to IR, 
thymocytes undergo apoptosis and are rapidly cleared by phagocytes. Whereas Wt mice 
showed a decrease in overall thymic size because of dead cell removal after IR exposure, 
DD1−/− mice showed less of a reduction in thymic size after IR exposure (Fig. 3A, top left). 
Quantification of cell numbers confirmed that IR-exposed DD1α−/− mice retained a larger 
thymic cell population than did control mice (Fig. 3A, bottom left). We observed similar 
changes in the spleen, another radiosensitive organ. IR clearly decreased the spleen size and 
weight of Wt mice, but DD1α−/− mice showed significantly less size reduction after IR (Fig. 
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3B). We also examined the presence of apoptotic cells in whole mounts of thymus at 
different times after IR exposure, by terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate nick end labeling (TUNEL) staining. Quantification of TUNEL-
stained cells was calculated as a fraction of DAPI (4′,6-diamidino-2-phenylindole)-positive 
cells using an imaging analysis program. In Wt and DD1α−/− mice, irradiation of 
thymocytes with IR induced a similar extent of apoptosis at 3 hours (~40%) and 6 hours 
(more than 80%). After 6 hours, apoptotic cells in Wt thymus were rapidly cleared down to 
40% at 12 hours and 20% at 18 hours. However, the clearance of apoptotic cells in DD1α−/− 
thymus was delayed, with twice as many apoptotic cells remaining in DD1α−/− thymus as in 
Wt thymus (Fig. 3A, right). Thus, DD1α functions in apoptotic corpse clearance in vitro and 
in vivo. Because apoptotic cells are typically cleared rapidly in vivo, they are rarely 
detectable histologically. We thus examined whether DD1α−/− mice displayed defects in 
scavenging apoptotic cells by TUNEL staining of tissue sections. In lymph nodes and 
colons, we observed 7- to 8-fold and ~17-fold increases, respectively, in TUNEL-positive 
cells in sections from DD1α−/− mice as compared with sections from Wt animals (Fig. 3C).
We asked whether DD1α also affected the phagocytic removal of apoptotic cells in a p53-
independent manner in vitro and in vivo. Treatment of dexamethasone (Dex) induces prompt 
and synchronous p53-independent cell death, and the consequent removal of apoptotic cells 
by phagocytes can provide a quantitative experimental model of apoptotic cell clearance in 
vitro and in vivo (43–45). Thymocytes isolated from Wt and DD1α−/− mice were exposed to 
Dex or IR to induce apoptosis. The apoptotic responses by IR and Dex were comparable 
(fig. S9A). Dex-induced apoptotic thymocytes from Wt and DD1α−/− mice were incubated 
with m-BMDMs isolated from Wt mice, and the phagocytic potential was assessed via flow 
cytometry–based analysis. Measurement of the m-BMDMs with increased red pHrodo 
signals among total m-BMDMs by flow cytometry revealed that Dex-treated apoptotic 
DD1α−/− thymocytes were less efficiently engulfed by macrophages than were Dex-treated 
apoptotic Wt thymocytes (fig. S9A, bottom). Wt and DD1α−/− mice were also treated with 
dexamethasone intraperitoneally. Whereas Wt mice showed a decrease in overall thymic size 
because of dead cell removal 6 hours after Dex injection, DD1α−/− mice showed less of a 
reduction in thymic size after Dex injection (fig. S9B, top left). Quantification of cell 
numbers confirmed that Dex-treated DD1α−/− mice retained a larger thymic cell population 
than did control mice (fig. S9B, top right). We also examined the presence of apoptotic cells 
in whole mounts of thymus at different times after Dex injection, by TUNEL staining. In Wt 
and DD1α−/− mice, Dex treatment induced a similar extent of apoptosis at 3 hours (~ 30%) 
and 6 hours (more than 80%). After 6 hours, apoptotic cells in Wt thymus were cleared 
down to ~35% at 12 hours and ~20% at 18 hours. However, the clearance of apoptotic cells 
in DD1α−/− thymus was delayed, with twice as many apoptotic cells remaining in DD1α−/− 
thymus as in Wt thymus (fig. S9B, bottom). We observed similar changes in the spleen. A 
decrease in spleen size and weight was apparent in Dex-treated Wt mice, but DD1α−/− mice 
showed less size reduction after Dex injection (fig. S9C). We also showed that there were no 
obvious differences in the steady-state levels of DD1α expression in multiple tissues 
between Wt and p53-null mice (fig. S10). Thus, DD1α functions in apoptotic corpse 
clearance by both p53-dependent and independent ways in vitro and in vivo, and phagocytic 
engulfment of apoptotic cells is impaired in the absence of DD1α.
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DD1α expression in macrophages is required for engulfment of apoptotic cells
DD1α is highly expressed on blood leukocytes (Fig. 1C) and in macrophages (fig. S11) and 
dendritic cells (37,38). Because of the expression of DD1α in phagocytes, we investigated 
whether DD1α expression in macrophages is also necessary for the engulfment of apoptotic 
cells. We used Wt- or DD1α-null thymocytes as prey and incubated them with Wt or 
DD1α−/− m-BMDMs for quantification of phagocytosis analysis using flow cytometry (Fig. 
4A). DD1α−/− m-BMDMs were deficient in uptake of pHrodo-labeled apoptotic Wt 
thymocytes, as compared with Wt m-BMDMs, but showed a similarly diminished 
engulfment rate when DD1α-null apoptotic thymocytes were used as prey. Phagocytosis 
analysis of Wt- and DD1α−/− m-BMDMs with synthetic beads (Fig. 4B) or bacteria (E. coli) 
(Fig. 4C) further revealed that DD1α−/− m-BMDMs have no defect in phagocytic ability, 
which suggests that DD1α-mediated engulfment is dependent upon the presence of DD1α 
in apoptotic cells but that engulfment of DD1α-independent targets is not. Thus, DD1α 
participates on both apoptotic cells and macrophages for engulfment of apoptotic cells.
PtdSer-independent engulfment of apoptotic cells by DD1α
Dying and/or apoptotic cells expose PtdSer on the outer leaflet of the surface membrane of 
apoptotic cells, which is considered a primary signal recognized by PtdSer receptor of 
phagocytes (1, 4). Therefore, we examined whether PtdSer is a ligand of DD1α receptor by 
protein lipid overlay assay. When membranes, spotted with 15 different lipids, were probed 
with DD1α recombinant proteins purified from several hosts, such as mammalian cells 
(293T human embryonic kidney epithelial cells), yeast, or Escherichia coli, DD1α did not 
bind to any lipids including PtdSer (fig. S12). To determine whether the DD1α pathway is 
functionally sufficient for apoptotic cell engulfment independent from PtdSer signaling, we 
knocked down DD1α expression in both Raji human lymphoma cells defective for PtdSer 
exposure (42, 46) and human acute T cell leukemia Jurkat cells defective for PtdSer 
exposure (42, 46, 47), and we treated cells with CPT to induce apoptosis and labeled them 
with pHrodo dye. The apoptotic Jurkat and Raji cells were then incubated with hu-MDM, 
and phagocytosis was determined as described in Fig. 2. Macrophages efficiently engulfed 
apoptotic Jurkat cells, but a lower number of apoptotic Raji cells were engulfed, as expected 
(fig. S13A). When DD1α-depleted Jurkat or Raji cells were mixed with hu-MDMs, 
engulfment by macrophages was still decreased in DD1α-depleted Raji cells at a similar 
ratio seen in DD1α-depleted Jurkat cells {phagocytic index of Jurkat cells: ~38 [control 
knockdown (KD)] to ~16 (DD1α-depleted); phagocytic index of Raji cells: ~15 (control 
KD) to ~5 (DD1α-depleted)} (fig. S13A). To further confirm the PtdSer signaling-
independent role of DD1α in apoptotic cell engulfment, the PtdSer-binding protein, annexin 
V, was used to inhibit PtdSer exposure, and then we examined phagocytic potentials in 
DD1α-overexpressing MCF7/DD1α-KD cells. As shown in fig. S13B, the treatment of both 
annexin V and antibodies (Abs) against DD1α blocking further inhibited phagocytic 
engulfment as compared with the treatment of annexin V or blocking Abs to DD1α. Thus, 
DD1α-mediated phagocytosis of apoptotic cells utilizes a different mechanism from the 
PtdSer pathway–initiated engulfment of apoptotic cells.
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Intercellular DD1α-DD1α interaction between apoptotic cells and phagocytes mediates 
apoptotic cell engulfment
So far, our data suggest that both DD1α on apoptotic cells and DD1α on phagocytes are 
required and interdependent for the engulfment of apoptotic cells. To examine the possibility 
of the DD1α-DD1α homophilic interactions, we studied interactions between beads coated 
with soluble proteins and cell surface–expressed receptor molecules, using a DD1α-Ig 
fusion soluble protein (DD1α-Ig) containing the extracellular domain or control Ig proteins 
[TIM-1-Ig and immunoglobulin (Ig)], in 293T transfected with Wt DD1α or mutant DD1α 
(IgV domain-deleted). DD1α-Ig proteins (but not control Ig proteins) bound to Wt DD1α 
proteins expressed on the cell surface, but deletion of the IgV domain abolished this 
interaction, which suggests the importance of homophilic DD1α binding through the IgV 
domain (Fig. 5A and fig. S14). To further test whether DD1α could interact with surface 
DD1α molecules, we used 293T cell transfectants expressing DD1α on the cell surface and 
several soluble Ig fusion proteins (DD1α-Ig, PD-L1–Ig, and TIM-1-Ig) for cell surface 
staining. DD1α-Ig, but not PD-L1–Ig or TIM-1-Ig, bound to DD1α transfectants on the cell 
surface (Fig. 5B). To analyze intercellular DD1α-DD1α binding, we used cell-cell adhesion 
assays. In addition, U2OS human osteosarcoma cells transfected with full-length DD1α, 
mutant DD1α with IgV domain deletion, or empty vector were incubated with CFSE-stained 
MCF7 cells with DD1α overexpression (MCF7-DD1α). After thorough washing to remove 
unbound green cells, the binding of green-labeled MCF7 cells to U2OS cells was quantified. 
U2OS cells with full-length DD1α overexpression showed greater binding to green-labeled 
MCF7-DD1α cells than did control vector or IgV domain–deleted DD1α mutant–
transfected U2OS cells, which confirmed the requirement for the IgV domain for potential 
intercellular DD1α-DD1α interactions (Fig. 5C). Homophilic intermolecular interaction for 
the DD1α receptor at intercellular junctions was further confirmed by two other 
experiments. Binding between DD1α-Myc and DD1α-HA was detected in lysates from 
cultures of 293T cells overexpressing Myc-tagged DD1α and 293T cells overexpressing 
HA-tagged DD1α by reciprocal coimmunoprecipitation (fig. S15A). We also performed a 
proximity ligation assay using Duolink in situ fluorescence assay to detect the association of 
DD1α-DD1α molecules between two different cell types, J774.1 (macrophage) and ZR75-1 
(breast carcinoma cell). Colocalization dots (generated by overlapping fluorescence signals) 
were detected at intercellular junctions (fig. S15B). Further confirming the specificity of 
intercellular binding, DD1α-transfected Jurkat cells (Jurkat-DD1α) were labeled with either 
cell tracer CFSE or Far Red, whereas control Jurkat cells were labeled with Far Red. CFSE-
labeled Jurkat-DD1α cells were incubated with Far Red–labeled Jurkat-DD1α cells or Far 
Red–labeled control Jurkat cells. DD1α-DD1α-mediated intercellular bindings were then 
analyzed by counting the percentage of CFSE- and Far Red–double-positive populations 
through flow cytometry. Incubation of differently labeled Jurkat-DD1α cell populations 
increased binding (~26%), but the binding between Jurkat-DD1α and control Jurkat cells 
was minimal (~3%) (Fig. 5D). To test whether soluble DD1α-Ig proteins compete or 
cooperate for intercellular DD1α-DD1α binding, we preincubated Jurkat-DD1α cells with 
soluble DD1α-Ig or Ig proteins. We found that exogenous treatment of DD1α-Ig modestly 
inhibited DD1α-DD1α-mediated intercellular binding between two differently labeled 
Jurkat/DD1α cell populations (Fig. 5D).
Yoon et al. Page 7
Science. Author manuscript; available in PMC 2017 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We mapped the binding region for DD1α-DD1α binding by in vitro binding analysis using 
glutathione S-transferase (GST)– and histidine (His)–fused DD1α variants and observed that 
the extracellular (amino acids 33–194) DD1α region or the immunoglobulin domain (37–
146) bound to the His-fusion protein containing only the extracellular portion of DD1α (33–
194) but not with IgV-deleted DD1α or the cytoplasmic region of DD1α, which indicated 
that the IgV domain is essential for DD1α-DD1α interactions (Fig. 5E). Cross-linking 
experiments using GST-fused DD1α variants also revealed self-association of the DD1α 
extracellular domain in solution (Fig. 5F, left). Cross-linked dimers were observed with the 
DD1α extracellular domain (33–194) variant in solution but not with the cytoplasmic region 
of DD1α. Dimerization of DD1α was also examined in intact cells (293T). DD1α-
transfected cells were incubated with or without bismaleimidohexane (BMH), another cross-
linker for covalent conjugation between sulfhydryl groups. The formation of the DD1α 
dimer was detected on nonreducing gels after treatment of cells with BMH (Fig. 5F, right).
We tested whether the extracellular IgV region functionally contributes to apoptotic cell 
engulfment with the IgV domain–deleted DD1α mutant (DD1α-ΔIgV). The full-length 
DD1α, mutant DD1α-DIgV, or empty control vector was transfected into DD1α-depleted 
MCF7 cells (fig. S16A), followed by induction of apoptosis (fig. S16B). Apoptotic MCF7 
cells were incubated with hu-MDMs for phagocytosis analysis. Apoptotic MCF7 cells 
expressing the full-length DD1α were efficiently engulfed by human macrophages, whereas 
apoptotic MCF7 cells expressing DD1α-ΔIgV mutant or control vector led to diminished 
phagocytosis by macrophages (Fig. 5G). To elucidate the possibility of the cis-dimerization 
for the DD1α-DD1α interaction, we performed a proximity ligation assay using the Duolink 
technology to detect the association of DD1α-DD1α molecules within the same cell. 
Colocalization dots were detected only in 293T cells overexpressing both DD1α-HA and 
DD1α-Myc (fig. S17), which suggests that DD1α interacts with itself in the trans, as well as 
in the cis, condition. Together, these data from biochemical and cellular assays demonstrate 
that there is likely a homophilic intermolecular interaction of the DD1α at intercellular 
junctions, as well as in the cis condition, that contributes to the engulfment of apoptotic 
cells. Our findings demonstrate an essential role for DD1α in dead cell clearance by 
phagocytes as the signal on both apoptotic cells and phagocytes.
DD1α-deficient mice develop autoimmune and severe inflammatory disorder
DD1α-null mice are viable, born at the expected Mendelian frequency, and indistinguishable 
in appearance from Wt littermates at an early age (48, 49). However, at the age of 7 to 10 
months, these mice show severe skin inflammation in adult female DD1α−/− mice (Fig. 6A). 
A majority of female DD1α−/− mice had ulcerative dermatitis and 35%, 23%, and 12% of 
female DD1α−/− mice showed otitis, eye-related inflammation, and seizures, respectively 
(Fig. 6A). Impaired clearance of apoptotic cells and accumulated corpses of dead cells can 
cause susceptibility to autoimmune disease (1, 3, 4). Because DD1α−/− mice showed severe 
skin inflammation (Fig. 6B), which is one of the clinical manifestations of systemic 
autoimmune disease, we examined whether DD1α−/− mice showed increased autoantibody 
titers. Starting at 8 to 10 months of age, the abundance of antinuclear antibodies (ANA) was 
increased in the sera of the phenotypically affected female DD1α−/− mice (Fig. 6C and fig. 
S18). Additionally, Abs to double-stranded DNA (dsDNA) were found in the serum from 
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DD1α−/− mice (Fig. 6C). Furthermore, total immunoglobulin G (IgG) in sera from 10-
month-old phenotypically affected DD1α−/− female mice was increased to ~6-fold in 
comparison with that of age-matched Wt mice (Fig. 6C). One of the most commonly 
targeted organs in systemic autoimmune disorders is the kidney (50). Consistent with other 
evidence of autoimmune activity, in the renal glomeruli of DD1α−/− mice, we observed 
immune complex deposition identified by immunofluorescence (Fig. 6D) and diffuse 
mesangial expansion as shown by periodic acid–Schiff (PAS)–positive material and cellular 
debris (Fig. 6D). Electron microscope analysis also showed an expanded mesangium with 
electrondense deposits and neutrophils within capillary lumens of DD1α−/− mice (Fig. 6D). 
Numerous large electron-dense deposits were also observed in electron micrographs of the 
glomerular mesangium of DD1α−/− glomeruli (Fig. 6D). Consistent with the above kidney 
phenotypes, DD1α−/− mice produced large amounts of protein in their urine (Fig. 6C). 
Together, the DD1α−/− kidney revealed a phenotype of active glomerulonephritis with a 
mesangioproliferative pattern of injury and immune complex deposition. We observed 
extensive splenomegaly and lymphadenopathy in DD1α−/− mice by 10 months of age (Fig. 
6E). Further histological analysis revealed extensive inflammatory infiltrates in skin and 
lung, and extramedullary hematopoiesis, including both erythroid and myeloid hyperplasia, 
was evident, which indicated a major immune dysregulated phenotype of DD1α−/− mice 
(fig. S19).
Inhibitory role of functional DD1α-DD1α interaction in T cell activation
Given the functional and biochemical homophilic DD1α-DD1α interaction between dead 
cells and macrophages, we next sought to determine whether such an interaction could also 
occur with naturally expressed DD1α on T cells. Thus, we used flow cytometry to assess 
binding of DD1α-Ig to surface receptors of CD4+ T cells. DD1α-Ig bound to human CD4+ 
T cells, but the binding of DD1α-Ig to T cells treated with blocking Abs to DD1α was 
decreased (fig. S20A). Moreover, this binding of DD1α-Ig to CD4+ T cells purified from 
DD1α−/− mouse was diminished as compared with its binding to Wt-CD4+ T cells (fig. 
S20B). Expression of DD1α on antigen-presenting cells (APCs) functions as a negative 
regulator or ligand of T cell response in vitro and its overexpression on tumor cells interferes 
with protective antitumor immunity in mice (37, 51). DD1α is also expressed on T cells and 
can function as a coinhibitory receptor of T cell activation (38, 49, 52). Moreover, 
preclinical studies with blocking Abs to DD1α enhanced antitumor T cell responses, leading 
to inhibited tumor growth and better survival (51).
Because intercellular DD1α-DD1α interaction is likely required for its scavenger function 
(Figs. 2 to 5) and DD1α is also expressed on the surface of CD4+ and CD8+ T cells (fig. 
S21), we further examined whether DD1α on CD4+ T cells functions as a receptor and 
causes DD1α-mediated inhibition of T cell activation. DD1α-Ig protein strongly inhibited 
proliferation of CD4+ and CD8+ T cells and cytokine production stimulated by CD3-specific 
Abs (fig. S22) (37). CD4+ and CD8+ T cells from Wt or DD1α−/− mice were used for 
DD1α-Ig–mediated T cell inhibition experiments. Engagement of DD1α-Ig inhibited CD3 
Ab–induced proliferation of CD4+ or CD8+ T cells (~50% inhibition). However, DD1α−/− 
CD4+ or CD8+ T cells were less sensitive to DD1α-Ig (~30% inhibition) (fig. S22), although 
DD1α deficiency did not prevent inhibition completely. These data indicate that potential 
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homophilic DD1α interactions are important for the DD1α-mediated T cell inhibitory role 
and that DD1α functions as a receptor on T cells. These findings indicate a role for tumor 
suppressor p53 in regulating expression of immune regulators, including PD-1, PD-L1, and 
DD1α, which suggests a potential role of p53 in immune responses.
Discussion
Our findings reveal that the tumor suppressor p53–induced expression of DD1α regulates 
efficient clearance of dead cells and proper immune tolerance. Although these two essential 
activities are seemingly interrelated, the complexity of these processes is demonstrated by 
the many receptors and signaling pathways involved in the recognition and removal of 
apoptotic cells by macrophages and stringent discrimination of self antigens from nonself 
antigens (1, 53, 54). We found that DD1α is a receptor that engages in homophilic 
intermolecular interaction or dimerization at intercellular junctions of apoptotic cells and 
macrophages, which is critical for the engulfment of apoptotic cells. Mice deficient in 
scavenger receptors develop spontaneous autoimmune disease (55–58), whereas deficiencies 
in dead cell clearance do not always elicit autoimmunity because these apoptotic cells in 
these deficiencies are still able to trigger a downstream immunosuppressive signal to inhibit 
autoimmunity (59, 60). In a normal immune system, phagocytic engulfment of apoptotic 
cells is accompanied by induction of a certain degree of immune tolerance in order to 
prevent self-antigen recognition (53, 61).
At age 10 to 12 months after birth, DD1α–deficient mice showed autoimmune phenotypes 
predominantly in female mice. These results imply that DD1α seems to be critical in dead 
cell clearance, and its loss directly affects immune tolerance. Previously reported DD1α 
knockout mice were generated by a gene-trapping approach targeting coding exon 1 (48). 
We achieved a Cre-mediated complete deletion of exons 2 and 3 of the DD1α gene, which 
resulted in the development of similar and yet exaggerated phenotypes with moderate to 
severe increases in size of certain organs and prominent formation of immune infiltrates in 
the skin, lung, liver, and kidney. Notably the autoimmune defects observed in the aged 
female DD1α mice were apparent even in the absence of other predisposing factors and 
resulted in an increased late mortality rate in females. Interestingly, the autoimmune 
phenotype characteristic for late-stage DD1α knockout animals is clearly prevalent in 
female mice. Importantly, similar gender bias has been previously described for various 
animal models of autoimmune disorders, such as SLE in which female animals are 
significantly more susceptible to the disease (55, 62). Also, sex hormones have been 
previously implicated in the development of high-affinity auto-reactive B cells (63). 
Epidemiological studies in humans also show extremely high (9:1) gender bias toward 
females for systemic autoimmune diseases (64).
The process of apoptotic-cell clearance involves extensive numbers of molecules. Based on 
resulting phenotypes of various knockout mice, it has been suggested that some molecules 
are critical for proper cell turnover during development (e.g., PSR, Beclin1, Atg5) (65–67), 
and other molecules are essential in the adult life, when rates of apoptosis in relevant tissues 
are physiologically normal during tissue homeostasis or when rates of apoptosis are 
accelerated under various stress stimuli (e.g., MFG-E8, TIM-4, SCARF1, C1q, CD14, Mer) 
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(55–58, 68, 69). Our data indicate that DD1α primarily responds to apoptotic stress and is 
more likely to be involved in the regulation of engulfment and phagocytosis of dead cells on 
the sites of extensive damage because of exogenously induced cellular toxicity. Additionally, 
public database information [EMAGE gene expression database (http://
www.emouseatlas.org/emage/)] shows that DD1α is almost not detectable at the embryonic 
stage, whereas PSR or Beclin1, which are involved in cell turnover during development, are 
markedly expressed in the embryo (70). Therefore, DD1α deficiency leads to accumulative 
defects of cellular clearance over prolonged time and results in an age-dependent 
autoimmune phenotype, which suggests the specific role of DD1α in a stress-responsive 
environment.
DD1α is expressed in immune cells, including macrophages and T cells, and likely 
functions as a receptor through DD1α-DD1α binding at intercellular junctions. We further 
demonstrated that DD1α has an important role as an intercellular homophilic receptor on T 
cells, which suggests that DD1α is a key-connecting molecule linking postapoptotic 
processes to immune surveillance. DD1α also appears to inhibit T cell activation. These 
findings establish a concept for cancer-driven control of immune surveillance: p53-
dependent genotoxic stress-mediated expression of DD1α and related immune checkpoint 
inhibitors, such as PD-1 and PD-L1 molecules on cancer cells, may enable their interactions 
with T cells in order to impose suppression of the immune response and escape from 
immune surveillance.
Materials and methods
Plasmids, transfection, and lentiviruses
For mammalian expression vector, full-length human DD1α cDNA was subcloned into 
pcDNA3.1(−) tagged with HA or Myc at the C terminus using standard procedure. 
Immunoglobulin V domain (amino acids 45–168)–deleted mutant DD1α-ΔIgV was 
generated by a PCR-mediated deletion method. For Fc-tagged soluble DD1α proteins 
(DD1α-Ig), the extracellular region of DD1α was cloned upstream of the mouse IgG-Fc 
region (DD1α-Ig) in the pCMV6-AC-FC vector (OriGene, Rockville, MD). Plasmid 
encoding TIM-1-Ig was a gift from Terry B. Strom (Transplant Institute, Beth Israel 
Deaconess Medical Center and Harvard Medical School, Boston, MA). To tag HA or Flag at 
the N terminus of DD1α, HA or Flag was inserted between DD1α signal peptide (SP) (1–
32) and DD1α peptide (33–311), resulting in the construction of SP (1–32)–HA-DD1α (33–
311) and SP (1–32)-Flag-DD1α (33–311). For recombinant DD1α deletion mutants, DD1α 
(33–194), DD1α (37–146), DD1α-DIgV (33–311, ΔIgV), and DD1α (215–311) were 
generated by PCR and subcloned into pGEX-6P-1 (GE Healthcare Life Sciences, Pittsburgh, 
PA). DD1α (33–194) was amplified and subcloned into pRSET vector (Invitrogen, Life 
Technologies, Grand Island, NY). For GST-fused p53 (93–312), p53 (93–312; DNA binding 
domain) was subcloned into pGEX-6P-1 (GE Healthcare Life Sciences). Transfections were 
performed using Lipofectamine 2000 (Invitrogen). Plasmids encoding lentivirus expressing 
DD1α-HA were generated by cloning DD1α-HA into pLenti CMV Neo DEST. Cells were 
transduced with lentivirus in the presence of polybrene. Infected cells were selected in 
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complete appropriate medium containing 10% fetal bovine serum (FBS) and G418 and were 
tested 1 week after infection.
Antibodies and additional reagents
The following Abs were used for Western blot analyses or flow cytometry analysis: p53 
(DO-1, Santa Cruz), p21 (DSC60, Cell Signaling Technology, Danvers, MA), β-actin 
(AC-15, Sigma-Aldrich, St. Louis), His (Invitrogen), GST (B-14, Santa Cruz), HA (F-7, 
Santa Cruz), HA (C29F4, Cell Signaling Technology), Myc (9E10, Santa Cruz), Ab against 
mouse DD1α (MH5A, BioLegend), Ab against human PD-1 (J116, eBioscience), Ab 
against human PD-L1 (M1H1, eBioscience), CTLA4 (C-19, Santa Cruz), ICOSL (LifeSpan 
BioSciences), Ab against human CD14 APC (61D3, eBioscience), Ab against mouse F4/80 
APC (BM8, eBioscience), Ab against mouse CD45R/B220 (RA3–6B2, eBioscience), Ab 
against human CD4-APC (OKT4, eBioscience), Ab against mouse CD4-APC (RM4–5, 
eBioscience), Ab against human CD8-APC (SK1, eBioscience) and Ab against mouse 
CD8a+-APC (53–6.7, eBioscience). Rabbit polyclonal and mouse monoclonal Ab against 
DD1α was raised against human DD1α (amino acids 33–311) as an immunogen. Beads 
immobilized with Abs against HA (Roche) or Myc (9B11, Cell Signaling) were used for 
immunoprecipitations. Recombinant human PD-1–Ig, mouse PD-1–Ig, human PD-L1–Ig, 
mouse PD-L1–Ig, and control Ig proteins were from R&D Systems.
Cells and culture conditions
EJ-p53 and EJ-CAT cells (human bladder cancer cell lines) (71) were cultured in the 
presence or absence of tetracycline (1 µg/ml) in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% FBS (Gibco), 100 units/ml of penicillin, and 100 µg/ml of 
streptomycin at 37°C (72). Human MCF7 (human breast cancer cell line), ZR75-1 (human 
breast cancer cell line), Saos-2 (human osteosarcoma cell line), U2OS (human osteo-
sarcoma cell line), A549 (human lung cancer cell line), A375 (human melanoma cell line), 
HEK293T (human embryonic kidney epithelial cell line), Hs888, and T (human 
osteosarcoma cell line) cells and J774 (mouse macrophage cell line) cells were maintained 
in DMEM (Cellgro) supplemented with 10% FBS and antibiotics. LOX-IMVI (human 
melanoma cell line), BxPC-3 (human pancreatic cancer cell line), Jurkat (human acute T cell 
leukemia cell line), and Raji (human Burkitt’s lymphoma cell line) cells were grown in 
Roswell Park Memorial Institute medium (RPMI) (Cellgro) supplemented with 10% FBS 
and antibiotics. For DD1α-overexpressing Jurkat cells, Jurkat cells infected with lentivirus 
carrying DD1α-HA were selected with 700 µg/ml geneticin, sorted, and subcloned. The 
BxPC-3 cells (73) were provided by D. Panigrahy (Beth Israel Deaconess Medical Center, 
Boston, MA). For treatment of DNA damage agents, cells were grown to ~50% confluency 
prior to exposure to DNA damage agent, CPT (0.5 to 20 µM), etoposide (25 µM), or IR (13 
Gy).
shRNA and siRNA experiments
Plasmids (pLKO.1-puro) expressing shRNAs against human DD1α-1 (5′-
GCAGAGACAACTTCTAAGAAT-3′; TRCN0000145473, Sigma-Aldrich) and DD1α #2 
(5′-GCACGATGTGACCTTCTACAA-3′; TRCN0000140372, Sigma-Aldrich) and pLKO.
1-puro Luciferase shRNA Control Plasmid DNA (Sigma-Aldrich) were purchased p53 
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siRNA (Validated Stealth RNAi siRNA, oligo ID: VHS40367) and control siRNA (Stealth 
RNAi Negative Control Low GC) were purchased from Invitrogen. shRNA plasmids and 
siRNAs were introduced into cells by transfection using Lipofectamine 2000 (Invitrogen) or 
X-tremeGENE siRNA Transfection Reagent (Roche), respectively. MCF7 or ZR75-1 cells 
stably expressing shRNAs were generated by selection with puromycin (1.0 µg/ml for 
MCF7,1.25 µg/ml for ZR75-1).
RNA analysis
RNA was prepared with TRIzol Reagent (Invitrogen) according to the manufacturer’s 
protocol. Total RNAs of human tissues were purchased from Clontech. The RNAs were 
analyzed by the Northern blot analysis as described previously (74). For real-time qPCR 
analysis, total RNAs were extracted with the Qiagen RNeasy kit with QIAshredder. cDNA 
was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). Primers were as follows: 
For human: DD1α: 5′-GATGTGACCTTCTACA-AGACG-3′ and 5′-
GTCCTGGAACGTGAGGTTGC-3′; PD-1: 5′-CCAGGATGGTTCTTAGACTCCC-3′ and 
5′-TTTAGCACGAAGCTCTCCGAT-3′; PD-L1: 5′-TGGCATTTGCTGAACGCATTT-3′ 
and 5′-TGCAGCCAGGTCTAATTGTTTT-3′; RPLP0: 5′-
CAGATTGGCTACCCAACTGTT-3′ and 5′-GGG-AAGGTGTAATCCGTCTCC-3′. For 
mouse: DD1α: 5′-GGAACCCTGCTCCTTGCTATT-3′ and 5′-TTGTA-
GATGGTCACATCGTGC-3′; Rplp0: 5-TCGGGTCCTA-GACCA-3′ and 5′-
AGATTCGGGATATGCTGTTGGC −3′. qPCR analysis was performed using an Icycler 
IQTM5 real-time system (Bio-Rad) with SYBER Green (Roche) for detection. Expression 
levels of genes analyzed by qPCR were normalized relative to levels of human RPLP0 or 
mouse Rplp0 expression.
Reporter plasmid generation and luciferase assay
A portion (1.7 kb) of the human DD1α promoter region was amplified by PCR and digested 
with SacI and XhoI and then was subcloned into luciferase expression vector 
(pGL4.21[luc2P/Puro], Promega). Transcription start site is marked as +1. For 6-kb 
promoter-report construct, the upstream of DD1α promoter from 1.7 kb to 6 kb was 
amplified by PCR and digested with KpnI and SacI, and then ligated into 1.7-kb DD1α 
promoter-luciferase construct. All constructs are verified by DNA sequencing. For luciferase 
assay, the luciferase reporter plasmids were transfected into cells. Vector encoding Renilla 
(pRL-TK) was also cotransfected for normalization of the transfection efficiency. The 
luciferase activity was determined using the Dual Luciferase Reporter Assay System 
(Promega).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation of IR-exposed MCF7 cells was performed following the 
manufacturer’s protocol (Upstate). Immunoprecipitation was carried out at 4°C overnight 
with polyclonal Ab against p53 and mouse IgG (Santa Cruz) as a negative control. 
Immunoprecipitated DNA was analyzed by qPCR with the following primers.
DD1α-BS1: 5′-ATATAGCAAGACCCCACCTCTACA-3′, 5′-
CACAGTGCAGCAACAAATAGAAGT-3′
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DD1α-BS2: 5′-CCTCAGGCTCTGAATCTACAGT-TA-3′, 5′-
GGGACAGAGACTTGTACCCTACAT-5′
p21: 5′-CTCACATCCTCCTTCTTCAG-3′, 5′-CAC-ACACAGAATCTGACTCCC-3′
The amount of immunoprecipitated DNA was normalized to inputs.
Electrophoretic mobility-shift assay
After etoposide treatment, nuclear extracts were collected from MCF7 cells using a general 
nuclear extraction method. Nuclear extracts (5 mg) or purified recombinant p53 was 
incubated with 32P-labeled oligonucleotides in gel shift binding buffer (5 mM Tris-HCl at 
pH 7.5, 20 mM NaCl, 0.5 mM MgCl2, 0.25 mM EDTA, 0.2% NP-40, 2.5% glycerol, 1 mM 
DTT, 20 µg/ml BSA, and 40 µg/ml poly(dI-dC). The DNA-protein complexes were resolved 
by electrophoresis through 5% polyacrylamide gel containing 0.5% TBE. Gels were dried 
and exposed to X-ray film. Unlabeled wild-type oligonucleotide or unlabeled mutant 
oligonucleotide was added in 100-fold excess as specific or nonspecific competitor. 
Oligonucleotides corresponding to the DNA binding consensus sequence for human p53 (75, 
76) were used.
DD1α-BS1: 5′-GCTGGGCATGGTGGTGCAT-GCCTGTA-3′
DD1α-BS1 Mut: 5′-GCTTTTTGCAGAGGTGT-CAAAGGTA-3′
DD1α-BS2: 5′-GTTAAACTGGCTCCAGCTTG-CCTAGC-3′
p21-BS: 5′-TGTCCGGGCATGTCCGGGCATGT-CCGGG-3′
p21-BS Mut: 5′-TGTCCGGGAATTTCCGGGAA-TTTCCGGG-3′
Preparation of human and mouse macrophages
For hu-MDM, human peripheral blood mononuclear cells were prepared from normal blood 
obtained from the Massachusetts General Hospital blood donor center (protocol number 
2012P002174). Monocytes were isolated by adhering mononuclear cells to culture plates for 
one hour at 37°C, after which nonadherent cells were removed by washing. The remaining 
cells were >95% CD14 positive. Adherent cells were then incubated in DMEM/F12 medium 
plus 10% FBS, 1% penicillin-streptomycin for 7 days to allow terminal differentiation of 
monocytes to macrophages (77). For mouse bone marrow–derived macrophages (m-
BMDM), femurs and tibias were harvested from 5- to 6-week-old mice and the marrow was 
flushed and placed into a sterile suspension of PBS. The bone marrow suspension was 
cultured in DMEM/F12 medium plus 10% FBS, 1% penicillin-streptomycin-glutamine with 
40 ng/ml recombinant murine macrophage colony-stimulating factor (M-CSF, Peprotech). 
Six days later, more than 90% of the adherent cells were CD11b positive and 80% of the 
cells were F4/80 positive.
Generation of apoptotic cells
Apoptosis of human cancer cells was induced by CPT (0.5 to 20 µM). To generate apoptotic 
thymocytes, thymocytes isolated from mice were exposed to the indicated dose of IR with 
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constant cell concentration of 1.0 × 106 thymocytes/ml. For phagocytosis assays, apoptotic 
cells were labeled with pHrodo or CFSE (carboxyfluorescein diacetate succinimidyl ester) 
(Invitrogen). Cells were used when 60 to 70% of cells were apoptotic, as defined by annexin 
V–positive and propidium iodide-negative staining or TUNEL staining by flow cytometry.
Phagocytosis assay
For flow cytometry analysis of phagocytosis, 2.0 × 105 BMDMs were plated in the 24-well 
plate 1 day before the phagocytosis assay. Next day, the cells were starved for 30 min with 
DMEM/F12 containing 2% FBS and incubated with fluorescently labeled targets, such as 
4.0 × 106 pHrodo (Invitrogen)-stained apoptotic thymocytes, 1 mg/ml pHrodo Red E. coli 
BioParticles (Invitrogen), or 2-µm carboxylate-modified latex beads (Invitrogen) in 150 µl of 
the uptake buffer (DMEM/F12 containing 2% FBS, 0.2% penicillin-streptomycin). After 
incubation for the indicated time, the cells were extensively washed with cold PBS, 
trypsinized and resuspended in cold medium containing 1% NaN3, and analyzed by flow 
cytometry. Forward and side-scatter parameters were used to distinguish unengulfed targets 
from phagocytes. The data were analyzed using FlowJo software. Fluorescent signal–
positive BMDMs were considered to be phagocytes engulfing targets (78). For time-lapse 
image analysis of phagocytosis, CFSE (Invitrogen)–labeled apoptotic thymocytes were 
added to BMDM with 1:5 ratio (BMDM:thymocyte). The individual BMDMs were 
monitoredbytime-lapse confocal microscopy imaging (Nikon Eclipse Ti and Zeiss LSM 
510), with images being taken at 1- to 2-min intervals. For image-based analysis of 
phagocytosis of human cancer cells, human monocyte-derived macrophages (MDMs) were 
prepared from human peripheral blood and incubated with pHrodo-labeled apoptotic cancer 
cells with 1:10 to 1:15 ratio (MDM: cancer cell). Two hours after coincubation, wells were 
washed thoroughly with cold serum-free RPMI five times and examined under a 
fluorescence microscope (Nikon Eclipse Ti or Zeiss AxioObserver.Z1) using bright field or 
Texas Red filter set. The phagocytic index was calculated using the following formula: 
phagocytic index = number of ingested cells/(number of macrophages/100), as described 
previously (79). At least 400 macrophages were counted per well.
Generation and genotyping of DD1α knockout mice
A targeting vector for the mouse DD1α gene was engineered by InGenious Targeting 
Laboratory, Inc. (Stony Brook, NY). In brief, a PGK-neomycin cassette flanked by loxP and 
FRT sites was inserted downstream of exon 3. A third loxP site was inserted upstream of 
exon 2. The targeted iTL BA1 (C57BL/6 × 129/SvEv) hybrid embryonic stem cells 
containing the linearized construct were microinjected into C57BL/6 blastocysts. Germline 
transmission was achieved by back-crossing chimeras to wild-type C57BL/6 mice. To 
generate the whole-body DD1α knockout mice, DD1αfloxneo; mice were first bred with β-
Actin/Flp mice (The Jackson Laboratory; catalog no. 003800) to remove the PGK-neomycin 
cassette and then bred with EIIa-Cre mice (The Jackson Laboratory; catalog no. 003724). 
Mice with DD1α heterozygous allele (DD1α+/−) were backcrossed with C57BL/6J mice for 
at least seven generations before being intercrossed to generate mice homozygous for the 
null allele (DD1α−/−). Routine genotyping was achieved on genomic DNA isolated from tail 
snips of mice with three primers to identify wild-type and null alleles: P1, 5′-
TCCTTGTGCAGGACAGAGTT-3′; P2, 5′-CTAATGGCACAGCAGGGACT-3′; and 
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P3,5′-CAACAAATCACGGTGGAGTG-3′. All animal experiments were approved by the 
Subcommittee on Research Animal Care of Massachusetts General Hospital (protocol no. 
2005N000022).
Analysis of apoptotic cell clearance in vivo
Four- to 5-week-old Wt and DD1α−/− mice were exposed to 6.6 Gy of IR or 
intraperitoneally injected with 250 µg dexamethasone as described previously (44, 45). At 
the indicated time points after exposure of IR or injection of dexamethasone, the mice were 
euthanized and thymuses and spleens were harvested. For quantification of total number of 
thymocytes in thymus, thymocytes were resuspended with PBS supplemented with 5% FBS. 
To monitor the TUNEL-positive apoptotic cells in thymus, 6-µm cryosections of whole 
thymuses were stained using the In Situ Cell Death TMR Red kit and DAPI according to 
manufacturer′s instructions (Roche). Whole-thymus images were obtained using an 
automated image stitching method under fluorescence microscope (Olympus FSX100). To 
quantify the clearance of TUNEL-positive cells, the percentage of TUNEL-positive cells 
was determined by the percentage of TUNEL-positive cells per DAPI-positive cells using an 
imaging analysis program (CellSens Dimension, Olympus).
Mouse serologic and urine analysis
The levels of total IgG, ANA, and ant-dsDNA in mouse serum were determined by enzyme-
linked immunosorbent assay according to the manufacturer’s instructions (Bio-Rad) with 
mouse serum at a dilution of 1:10 to 1:50. For immunofluorescent analysis of ANA, HEp-2 
slides were used. The images were analyzed by fluorescence microscope (Olympus 
FSX100). For mouse urine analysis, 24 hours albuminuria was measured using metabolic 
cages. Of note, mice were fed a 5% sucrose drinking solution during the 24 hours analysis in 
the metabolic cages. Urine (10 µl) was analyzed by SDS-PAGE and Coomassie blue 
staining. Bovine serum albumin (0.25, 0.5, 1.0, 2.5, and 5.0 µg) served as standard. Signals 
were quantified using ImageJ software (NIH). Resulting values of the 5 multiplication of the 
“size of the area” and the “mean gray value” of each albumin standards were used for 
construction of a standard curve and its associated mathematical function. Values were 
translated into albumin concentrations and extrapolated to 24-hour urine volume.
Histology and transmission electron microscopy
Organs were fixed by retrograde vascular perfusion with 4% paraformaldehyde in PBS, 
removed, and immersed in the same fixative for a maximum of 2 days until further 
processing for histology, immunohistochemistry, or transmission electron microscopy 
(TEM), as previously described (80). For immunocomplex analysis, frozen sections were 
used. 4 µm paraffin-processed formalin-fixed tissue sections were stained with Periodic Acid 
Schiff (PAS) or hematoxylin/eosin (H&E). Images were taken with an Olympus BX53 
microscope with DP72 camera and processed using Adobe PhotoShop software. Ultra-thin 
80-nm sections of resin-embedded kidney tissue were mounted on copper grids, treated with 
uranyl acetate and lead citrate, and examined by a pathologist (A.W.) in a blinded fashion 
using a JEOL 1010 transmission electron microscope (Tokyo, Japan).
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Homophilic interaction assay
Protein A/G–purified DD1α-Ig proteins or Ig proteins (control) were covalently coupled to 6 
mm blue carboxylated microparticles as recommended by the manufacturers (Polyscience, 
Inc.). 293T cells were transfected with the plasmids expressing full length DD1α, DD1α-
ΔIgV, or control empty vector as indicated amount per well of six-well culture plates for 24 
hours. The transfected cells were incubated with the Ig protein–coated beads in PBS 
containing 2% FBS at room temperature. After 30 min, unbound beads were washed with 
cold PBS and cell monolayers in culture media examined under an inverted microscope, and 
the binding was determined by measuring the optical density (O.D.) at 492 nm (81).
In situ proximity ligation assay
The assay was performed with the use of a Duolink using PLA Technology (Sigma-Aldrich). 
J774.1 macrophages and ZR75-1 breast cancer cells were transfected with plasmids 
encoding DD1α-HA or DD1α-Myc, respectively, for 24 hours. The transfected cells were 
trypsinized and cocultured on slide glasses in six-well culture plates. After 24 hours, cells 
were fixed, permeabilized, blocked, and then incubated with rabbit HA–specific Ab and 
mouse Myc–specific Ab at 4°C overnight. The cells were then subjected to an in situ 
proximity ligation assay with PLA probes, according to the manufacturer’s protocol. All 
images were taken with a Nikon Eclipse Ti confocal microscope and processed using Adobe 
Photoshop software with minimal adjustment of brightness or contrast.
In vitro binding assay
His-fused DD1α (33–194) and GST-fused DD1α variants were purified from bacteria using 
Ni-NTA agarose (Life Technologies) or glutathione-Sepharose beads (GE Healthcare Life 
Sciences), respectively. For binding of His-DD1α (33–194) to Ig fusion proteins (DD1α-Ig, 
PD-1–Ig, or Ig), Ig-fused proteins were immobilized on protein A/G agarose. The His-fused 
DD1α (33–194) protein was incubated at 4°C for 4 hours in a binding buffer containing 20 
mM HEPES, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 5 mM CaCl2,1 mM DTT, 0.1% NP-40, 
and 100 µg/ml BSA with GST-fused proteins immobilized on glutathione-agarose beads or 
Ig-fused proteins immobilized on protein A/G. The bound His-fused protein was eluted from 
the beads and analyzed by SDS-PAGE and Western blot using His-specific Ab.
Protein lipid overlay assay
Membrane lipid strips (Echelon Bioscience) prespotted with 15 different biologically active 
lipids, at 100 pmol per spot, were purchased. Nonspecific binding of membranes was 
blocked by incubation for 18 hours with 3% BSA in TBS-T (50 mM Tris at pH 7.4, 0.5 M 
NaCl, and 0.1% Tween-20). After blocking, membranes were incubated for 2 hours with 2 
µg/ml of soluble recombinant proteins, such as DD1α-Ig purified from mammalian cell, 
DD1α-His purified from yeast, His-DD1α purified from bacteria, and TIM-1-Ig, and then 
were washed and incubated with indicated Abs, followed by incubation for 1 hour with a 
horseradish peroxidase–labeled secondary Ab. Binding was detected by chemiluminescent 
detection.
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T cell activation assay
The cell culture plates were coated with CD3-specific Ab (OKT3, eBioscience for human T 
cells; 145-2C11, eBioscience for mouse T cells) and various concentrations of DD1α-Ig or 
PD-L1–Ig. The amount of Ig protein was kept constant at 10 mg/ml by the addition of 
control Ig protein. Mouse CD4+ and CD8+ T cells were purified from splenocytes freshly 
isolated from mice using CD4+ T Cell Isolation Kit II, mouse or CD8a+ T Cell Isolation Kit 
II, mouse (Miltenyi Biotec). Purity was confirmed to be over 90% by flow cytometry. The T 
cells were labeled with 1 µM CFSE, quenched by cold FBS, and incubated in plates coated 
with CD3-specific Ab and Ig proteins. On day 2 after stimulation, supernatant was collected, 
and cytokines were assayed by ELISA. On day 3, cells were stained with Ab against CD4-
APC (RM4–5, eBioscience for mouse CD4+ T cells) or Ab against CD8-APC (53–6.7, 
eBioscience for mouse CD8+ T cells) and then analyzed for CFSE dilution by flow 
cytometry.
Binding assay of Ig fusion proteins to T cells
Purified human CD4+ T cells from freshly isolated PBMCs were stimulated by plate-bound 
CD3-specific Ab (5 µg/ml) for 3 days, collected, and then preincubated with 100 µg/ml 
DD1α-specific or control mouse IgG1 Ab for 30 min. Cells were then washed and incubated 
with 30 µg/ml DD1α-Ig or control Ig proteins (Fc portion; human IgG1; R&D Systems) for 
30 min. After washing once with PBS, cells were incubated with antihuman IgG (5 µg/ml), 
cross-absorbed against mouse Ig (Southern Biotech), and washed twice with PBS. The 
bound Ig fusion proteins were analyzed by flow cytometry (82, 83).
Statistical analysis
Statistics were calculated using Prism 6.0 software (GraphPad Software). For analysis of 
statistical difference between experiments involving two groups, a Student’s two-tailed t test 
was applied. A one-way analysis of variance (ANOVA) was applied for statistical analysis of 
three or more groups. Significance was defined when P values were <0.05.
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Fig. 1. Identification of DD1α as a p53 target gene
(A) p53-dependent expression of DD1α. DD1α mRNA and protein were assessed after 
tetracycline (tet) removal in EJ-p53tet cells (tet-off) (top). MCF7 cells (bottom) were 
transfected with either siRNA targeting p53 or luciferase control for 24 hours, then treated 
with CPT (500 nM). MCF7 cells were treated with Nutlin-3 (10 µM) for the indicated times. 
Northern blots were used to determine mRNA expression of p53, DD1α, p21, and 36B4. 
Western blotting was performed with specific Abs against p53, DD1α, p21, and β-actin. (B) 
p53 binds to and transactivates the DD1α promoter. Luciferase reporter constructs 
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containing the putative p53 recognition sites in the DD1α promoter were cotransfected with 
either Wt-p53, mutant p53 (V143A), or pcDNA3.1 empty vector into U2OS cells. Results 
represent mean ± SD from three experiments. ChIP was performed on MCF7 cells exposed 
to IR (13 Gy). Immunoprecipitation was carried out with Ab against p53 (DO-1) or mouse 
IgG (negative control). The % input of coprecipitating DNAs was measured by qPCR and 
presented as mean ± SD (n = 3). (C) The expression of human DD1α mRNA was analyzed 
by Northern blotting from various human tissues, including blood leukocyte (Lk), lung (Lu), 
placenta (PI), small intestine (SI), liver (Li), kidney (Ki), spleen (Sp), thymus (Tm), colon 
(Co), skeletal muscle (Sm), heart (He), and brain (Br). Multiple sequence alignment of the 
IgV domains of DD1α and its homologous proteins. The predicted secondary structures are 
shown below the alignment as blue e for β strand and red h for α helix. The identical amino 
acids are in red box, the conserved amino acids are in yellow box, and the consensus amino 
acids are in green box. (D) p53-dependent expression of immune checkpoint regulators 
PD-1 and PD-L1. MCF7 cells were treated with 10 µM Nutlin-3 for 1 to 3 days. MCF7 cells 
were transfected with control siRNA or p53 siRNA for 24 hours and treated with 500 nM 
CPTor DMSO for 1 or 2 days. The levels of indicated proteins (TIM-1, TIM-3, TIM-4, PD-
L1, and PD-1) were analyzed by Western blot analysis. Total RNAs from control siRNA or 
p53 siRNA transfected MCF7 cells were assessed for mRNA levels of PD-1 or PD-L1 by 
real-time quantitative PCR. PD-1 or PD-L1 mRNA levels were normalized to 36B4 
expression and shown as mean ± SD (n = 3). ZR75-1 cells treated with 500 nM CPT or 
A375 cells exposed to IR (13 Gy) for indicated times.
Yoon et al. Page 24
Science. Author manuscript; available in PMC 2017 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. DD1α plays essential roles in apoptotic cell engulfment
(A) DD1α on apoptotic cells contributes to apoptotic cell engulfment. MCF7 cells were 
transfected with shRNAs including control (luciferase) or DD1α (two different target 
sequences: #1, #2) or p53 (two different target sequences: #1, #2) and were treated with CPT 
(10 to 20 µM) for 48 hours to induce apoptosis. Then, apoptotic MCF7 cells were labeled 
with pHrodo, incubated with hu-MDMs for 2 hours, and examined by immunofluorescence 
microscopy to detect phagocytosis (red fluorescence: engulfed MCF7 cells). Where 
indicated, MCF7 cells expressing DD1α shRNA (#1) were transfected for 24 hours with 
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siRNA targeting p53 or a vector encoding DD1α before the phagocytosis assay. More than 
400 macrophages were counted. Data are mean ± SD from three experiments. The 
representative images of phagocytosis with control, DD1α, p53, both DD1α and p53 
knockdowned, and DD1α-reintroduced MCF7 cells plus hu-MDMs are shown. Scale bar, 
100 µm. (B) Resistance of DD1α−/− cancer cells to phagocytosis. Phagocytic indices of 
DD1α-induced cancer cells (MCF7, ZR75-1, A375), DD1α-nonresponsive cancer cells 
(BxPC-3, Hs888. T), and DD1α-reintroduced DD1α-absent cancer cells (BxPC-3/DD1α, 
Hs888T/DD1α) were determined using hu-MDMs, as shown in Fig. 2A. The levels of 
DD1α protein were examined by Western blot analysis. (C) Engulfment of Wt, DD1α−/−, 
and p53−/− apoptotic thymocytes by mouse bone marrow–derived macrophages (m-
BMDMs) isolated from Wt mice was assessed by flow cytometry analysis. Thymocytes 
isolated from Wt, DD1α−/−, or p53−/− mice were exposed to IR (2 to 10 Gy) to induce 
apoptotic populations. The pHrodo-labeled mouse thymocytes (live or apoptotic: live Wt, 
dead Wt, dead DD1α−/−, or dead p53−/−) were incubated with Wt m-BMDMs for 30 min. 
Phagocytosis was determined by the percentage of macrophages containing positive pHrodo 
signal. Data are shown as mean ± SD and representative of three independent experiments. 
(D) Engulfment of Wt, DD1α−/−, and p53−/− apoptotic thymocytes by m-BMDMs was 
assessed by time-lapse imaging analysis. CFSE (green)–labeled apoptotic Wt, DD1α−/−, or 
p53−/− thymocytes were incubated with PKH26 red-labeled Wt m-BMDMs. The images of 
phagocytosis were taken every 1 min after incubation. The representative images of 
engulfments were shown, and arrowheads indicate the engulfed thymocytes. Data represent 
mean ± SD from three different experiments.
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Fig. 3. Impaired clearance of apoptotic cells in the DD1α-null mice
(A) Photographs of representative thymus from Wt and DD1α−/− mice at indicated time 
points after exposure or nonexposure to IR (6.6 Gy). Total cell numbers per thymus from Wt 
and DD1α−/− mice were determined at 8 hours after ionizing irradiation. Mean ± SD, n = 4 
per group. **P < 0.01 (Tukey’s test). The right panels represent whole sections of thymus 
from Wt and DD1α−/− mice exposed to IR that were stained with TUNEL (red) and 4′,6-
diamidino-2-phenylindole (DAPI; blue). Scale bar, 1 mm. The percentage of TUNEL-
positive cells was determined by percent of the TUNEL-positive cells per DAPI-positive 
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cells using imaging analysis program (CellSens Dimension, Olympus). Data represent mean 
± SD, n = 4. (B) Spleens of Wt and DD1α−/− mice exposed to IR. Four- to five-week-old Wt 
and DD1α−/− mice were treated with 6.6 Gy IR. After 6 hours, spleens were isolated from 
mice and the splenic weight was measured. The photograph of representative spleens of Wt 
and DD1α−/− mice exposed to IR is shown. Each dot represents the value for a single 
mouse, and mean ± SD (n = 5) is shown. **P < 0.01 (Tukey’s test). (C) Apoptotic cells in 
lymph nodes and colon of Wt and DD1α−/− mice. The cryosections were stained with 
TUNEL and DAPI. The apoptotic cells were determined by counting TUNEL-positive cells 
per mm2 under a fluorescence microscope. Mean ± SD, n = 3. Scale bar, 50 µm.
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Fig. 4. DD1α expression on macrophages is required for apoptotic cell engulfment
(A) Engulfments of apoptotic thymocytes by Wt and DD1α−/− m-BMDMs were assessed by 
flow cytometry. The pHrodo-labeled apoptotic thymocytes were incubated with m-BMDMs 
for 30 min, and the phagocytosis was determined by measuring the positive pHrodo-
containing macrophages. Graph represents mean ± SD from three experiments. (B) DD1α 
deficiency in macrophages does not influence engulfment of synthetic beads. Bone marrow–
derived macrophages (m-BMDM) from Wt and DD1α−/− mice were incubated with 
carboxylate-modified green fluorescent beads (synthetic beads) for indicated times. The 
phagocytosis was determined by the percentage of macrophages containing positive green 
fluorescence signal. Data are shown as mean ± SD and are representative of three 
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experiments at the same time. (C) The phagocytic potential of Wt and DD1α−/− m-BMDMs 
for E. coli was assessed using pHrodo-labeled E. coli. The phagocytosis was determined by 
the percentage of macrophages containing positive pHrodo signal. Data represent mean ± 
SD (n = 3) and are representative of three experiments at the same time.
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Fig. 5. Intercellular homophilic DD1α interaction between apoptotic cells and phagocytes 
mediates apoptotic cell engulfment
(A) Homophilic DD1α interaction. Binding of blue latex beads coated with DD1α-Ig fusion 
proteins (the extracellular region of DD1α fused with the immunoglobulin G Fc segment) to 
293T cells transfected with empty vector (EV), the Wt DD1α (2 or 10 µg), or a mutant 
lacking the IgV domain (DD1α-ΔIgV). Ig protein–coated beads were included as control. 
After 30 min, unbound beads were washed. The binding was examined under an inverted 
microscope (left) and also determined from the optical density (O.D.) at 492 nm (right). 
Data are shown as mean ± SD and are representative of three experiments. Scale bar, 50 µm. 
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(B) Interaction of DD1α with DD1α on the cell surface. 293T cells stably transfected with 
DD1α cDNA were stained with DD1α-Ig, PD-L1–Ig, TIM-1-Ig, or control Ig proteins (gray 
filled). The binding of Ig proteins was detected with Ab against human IgG1-PE. Binding 
amounts were determined by percentage of fluorescence-positive cells compared with 
control Ig protein–bound cells. (C) Intercellular DD1α interaction. Binding of CFSE-labeled 
DD1α-overexpressing apoptotic MCF7 cells to U2OS cells expressing empty vector (EV), 
full-length DD1α, or DD1α-ΔIgV (IgV deletion mutant). Scale bar, 100 µm. Binding was 
determined by counting the bound cells per 100 µm2 and normalized by cell number bound 
to untreated plate. Mean ± SD of three experiments is shown. (D) Intercellular DD1α-DD1α 
interaction and the disruption by recombinant DD1α proteins. The exogenous expression of 
DD1α in Jurkat cells was validated by flow cytometry analysis (left). CFSE-labeled DD1α-
overexpressing Jurkat cells were pre-incubated with Ig proteins (control Ig: 50 µg/ml; 
DD1α-Ig: 25 µg/ml for #1,50 µg/ml for #2) for 30 min and mixed with Far Red–labeled 
control or DD1α-overexpressing Jurkat cells. After 1-hour incubation, DD1α-DD1α-
mediated intercellular bindings were analyzed by counting the percentage of CFSE-and Far 
Red-positive populations (right). (E) Mapping of binding site for homophilic DD1α 
interaction. His-DD1α (33–194) protein was incubated with GST-DD1α variants (the 
extracellular region, 33–194; the immunoglobulin domain, 37–146; IgV-deleted mutant, the 
cytoplasmic region, 215–311) immobilized on glutathione-agarose beads. The bead-bound 
His-DD1α (33–194) proteins were eluted and detected by immunoblotting using Ab against 
His. A portion (5%) of the input proteins for the binding reaction was also subjected to 
immunoblotting. (F) Self-association of the extracellular region of DD1α in solution. GST-
DD1α (33–194), GST-DD1α (215–311), or control protein GST was untreated or treated 
with 2.5 mM BS3 cross-linker for 1 hour at 4°C, and GST proteins were analyzed by 
Western blotting using Ab against GST (left). Dimerization of DD1α was also examined in 
intact cells. DD1α-transfected 293T cells were treated or untreated with 1 mM 
bis(maleinido)hexane (BMH) for 1 hour, and DD1α protein was analyzed by Western 
blotting under nonreducing condition (right). (G) Extracellular IgV domain is required for 
engulfment. DD1α, DD1α-ΔIgV (IgV-deleted DD1α mutant), and control empty vector 
were reintroduced into DD1α-depleted MCF7 cells, and the cells were treated with DMSO 
or CPT (10 µM) for 48 hours. The phagocytosis of MCF7/DD1α knocked-down cells 
expressing empty vector (EV), DD1α, or DD1α-ΔIgV was determined as in Fig. 2A. Graph 
represents mean ± SD (n = 3). Scale bar, 50 µm.
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Fig. 6. DD1α-deficient mice develop autoimmune and severe inflammatory disorder
(A) Inflammatory phenotype of DD1α−/− mice. DD1α−/− mice (34 females, 39 males) and 
control Wt mice (34 females, 35 males) were observed over a 19-month period. The left box 
summarizes the symptoms (ulcerative dermatitis, otitis, seizure, and eye lesion) and 
incidences of symptoms. Photographs of 13- or 15-month-old female Wt and DD1α−/− mice 
are shown. (B) Dermatitis incidence in DD1α−/− mice (34 females and 39 males) and 
control Wt mice (34 females and 35 males). *P < 0.001 (Log-rank test). (C) The levels of 
ANA and Abs against dsDNA in sera of phenotypically affected female Wt and DD1α−/− 
mice were measured by ELISA. (Wt: n = 20, DD1α−/−n = 24 for ANA; and Wt: n = 19, 
DD1α−/−: n = 23 for Abs against dsDNA). Each dot represents the value for a single mouse. 
**P < 0.01, *P < 0.05 (Student’s t test). Serum IgG levels of phenotypically affected 10-
month-old female Wt and DD1α−/− mice (n = 7) were assessed by ELISA. The level of 
albumin in urine collected for 24 hours from affected 10- to 12-month-old female mice (n = 
8) was analyzed by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and imaging 
analysis. (D) Spontaneous glomerulonephritis in DD1α−/− mice. Representative images of 
kidney sections from 10-month-old Wt and DD1α−/− mice stained with Ab against mouse 
IgG show immune complex deposits in glomeruli of DD1α−/− mice (the first column of 
panels). Scale bar, 20 µm. The second column of panels shows kidney sections from Wt and 
DD1α−/− mice stained with PAS. Glomeruli from Wt mice have a regular architecture with 
delicate mesangium. Glomeruli from DD1α−/− mice with dermatitis symptoms show diffuse 
mesangial expansion by PAS-positive material and cellular debris (arrowhead), as well as 
occasional neutrophils within capillary lumens (arrow). Scale bar, 50 µm. The third column 
of panels shows low-magnification electron micrographs of Wt and DD1α−/− glomeruli. A 
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normal architecture with delicate mesangium and intact filtration barrier of Wt glomeruli 
and an expanded mesangium with electron-dense deposits, and neutrophils within capillary 
lumens (arrows) of DD1α−/− glomeruli are shown. Scale bar, 2 µm. The fourth column of 
panels show high magnification electron micrograph of the glomerular mesangium of Wt 
and DD1α−/− glomeruli. Large electron-dense deposits (arrows), often with tubular 
substructure in the glomerular mesangium of DD1α−/− glomeruli are shown. Scale bars, 2 
µm (top) and 500 nm (bottom). (E) Splenomegaly and lymphadenopathy observed in 
DD1α−/− mice. Spleens and lymph nodes of 10-month-old female Wt and DD1α−/− mice 
from one littermate were shown. The weight of spleen and lymph nodes was measured as 
indicated. Data represent mean ± SD. n = 6 to ~11 mice per group.
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